<DOC>
	<DOCNO>NCT00418639</DOCNO>
	<brief_summary>This study evaluate effect treatment 24 week nitazoxanide monotherapy end treatment virologic response , sustain virologic response , reduction quantitative serum HCV RNA , change ALT safety parameter .</brief_summary>
	<brief_title>Study Nitazoxanide Treatment Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Age â‰¥ 18 year . Chronic hepatitis C infection ( least 6 month ) evidence positive enzyme immunoassay antiHCVantibodies positive quantitative RTPCR amplification HCV RNA . Chronic inflammation liver biopsy compatible diagnosis chronic viral hepatitis . Patients unable take oral medication . Use interferon alpha within 90 day ribavirin within 30 day prior enrollment . Females child bear age either pregnant , breastfeed use birth control sexually active . Any investigational drug therapy within 30 day prior enrollment . Patients cause liver disease . Patients coinfected hepatitis A virus , hepatitis B virus hepatitis D virus base enzyme immunoassay . Patients history alcoholism alcohol consumption &gt; 40 gram per day . Patients clinically unstable . Patients concomitant condition , opinion investigator would preclude evaluation response make unlikely contemplated course therapy followup could complete . History hypersensitivity intolerance nitazoxanide excipients comprise nitazoxanide tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>